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RESEARCH BRIEF

Leveraging Science to Treat a
Neglected Tropical Disease
By Katherine Unger Baillie

A

bite from a tiny sand fly can be nearly imperceptible. But the aftermath can be devastating.
Sand flies are the vectors for leishmaniasis, a
parasitic disease that affects 12 million people
in the tropics, as well as dogs and other mammals. The
cutaneous form of the disease causes unsightly skin ulcers
that take months or even years to heal, and can progress to
cause severe, disfiguring tissue damage.
“This is classically what you would call a ‘developingworld disease,’ since it gets little attention,” says Dr. Phillip
Scott, Vice Dean for Research and Academic Resources and
Professor of Immunology at Penn Vet. “There is no vaccine
and the drugs that are currently used to treat this disease are
not very effective and can be quite toxic.”
For more than three decades, Scott has been partnering
with scientists in Brazil and across Penn to better understand
the underlying biology of the disease, with a goal of
identifying treatments that are both safe and effective. They
are already moving from laboratory bench to bedside, with
plans for a clinical trial.
Leishmaniasis is a particularly insidious disease because the
parasite lives and replicates inside the very cells that would
normally kill it: macrophages. After a bite from an infected

32 BELLWETHER FALL 2015

DR. PHILLIP SCOTT

sand fly, the parasite enters the skin; macrophages engulf the
parasite and recruit T cells to help vanquish the infection. T
cells, in turn, produce interferon gamma (IFNγ), a signaling
molecule that instructs macrophages to kill off the pathogen.
Yet when researchers took tissue samples from people
with leishmaniasis infections, they observed something
puzzling. Some patients who had low levels of parasite and
high levels of IFNγ, indicating that the immune system was
strongly responding to the infection, still had extremely
severe forms of the disease. This scenario of low parasite
levels yet high IFNγ is particularly common in parts of
Brazil, where Scott has worked in a clinic that sees about
1,500 leishmaniasis patients each year.
“Whenever you have this spectrum of clinical
presentation, you can’t help but wonder, ‘Why does that
happen?’ In my lab, we’re looking for ways to modulate the
immune response to help patients avoid the most horrific
forms of this disease,” Scott says.
To investigate the reasons why some patients suffer such
serious forms of leishmaniasis, Scott and colleagues have
conducted studies in mice in his lab at Penn Vet, and in
human patients at the Brazilian clinic—located in Corte de
Pedra, about 3.5 hours from Brazil’s first capital, Salvador.
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(At left) The life cycle of leishmaniasis; (At right) The infective stage of
the Leishmania parasite in the presence of two types of macrophages
(stained blue and green) that the parasite can infect.

The work, which has been supported in large part by
National Institutes of Health grants awarded to Scott,
has pointed to an unexpected culprit in severe cutaneous
disease: a type of T cell called CD8 cells.
In some cases, these cells can help clear leishmania
infection. But they also have a dark side. Working with
postdoctoral researcher Fernanda Novais, a native Brazilian,
Scott used a spinning disk confocal microscope to make
videos of mouse T cells attacking the leishmania parasite.
They saw that CD8 cells can actually lyse, or pop open,
infected macrophages. Like poking at a hornet’s nest, the T
cells end up exacerbating disease by releasing live parasites
and inflammatory factors from macrophages, which can then
diffuse into surrounding tissue, inflaming tissue and causing
skin lesions to worsen.
With this new model of leishmaniasis pathology in hand,
Scott’s lab and partners in Brazil have begun trying to
understand the factors that help determine whether CD8
cells are helpful or harmful—an understanding that may one
day lead to a vaccine or new therapies.
In collaboration with John Wherry, Professor in the
Department of Microbiology at Penn’s Perelman School
of Medicine, Scott found that having a prior viral infection
before acquiring leishmaniasis can lead to a more aggressive
form of disease, likely because the immune system’s CD8
T cells have already been primed to respond to invading
pathogens.
In addition, a partnership with Elizabeth Grice, Assistant
Professor in the Department of Dermatology at Penn
Medicine, has focused on the role of the skin microbiome—
the collected community of bacteria, viruses, parasites,
and other microbes—in disease progression. In mice,
they’ve found that leishmaniasis infection transforms the
microbiome, causing certain types of microbes to become
dominant that they believe may exacerbate disease. One
possibility is that using an antibiotic to reduce populations
of these dominant microbes could supplement and boost the

effectiveness of standard leishmaniasis therapies.
Scott and his Brazilian colleagues are also embarking
on a new project that will use blood and tissue samples
from patients in Brazil to further elucidate the biology of
the disease. Researchers will obtain genomic sequences
from parasites, analyze the patients’ skin microbiomes, and
perform transcriptional analyses on lesion tissue compared
to normal tissue to see what genes are activated during
infection.
“With this work, we’ll get a full picture of what’s
happening in these patients,” Scott says. “One thought is
that we could define biomarkers for progression to serious
disease or perhaps even drug targets.”
For now, however, researchers are hoping to leverage
drugs that are already on the market to make an impact
against leishmaniasis. First up is an inflammation-blocking
compound called anakinra, which is widely used to treat
rheumatoid arthritis. Scott’s lab has shown that anakinra is
extremely effective against leishmaniasis in mice; now he
is helping design a clinical trial that will enroll a handful of
human patients in Brazil.
“Most tropical diseases don’t get the attention of drug
companies, so if we can use a drug that is already available
to effectively treat leishmaniasis, it’s a win-win,” Scott says.
Parasitic diseases have largely been wiped out in humans
in the developed world. But since they remain a problem
in companion animals, veterinary schools—including Penn
Vet—have a strong history in the field of parasitology. Scott
and his fellow scientists are continuing in this tradition,
applying the concept of One Health to understand parasite
biology and, perhaps one day soon, reap important benefits
for human and animal health around the world.
“Working on this disease provides an opportunity to do
some really interesting basic science with a great team and,
what’s even more exciting, to do something that might help
a lot of people,” Scott says.
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